PDF(Pubmed)
Abstract：
UNASSIGNED: Despite the increasing availability of therapeutic drugs for autoimmune diseases, many patients still struggle to achieve their treatment goals. Our aim was to identify whether drugs originally used to treat bone density could be applied to the treatment of autoimmune diseases through Mendelian randomization (MR).
UNASSIGNED: Using summary statistics from genome-wide association studies, we used a two-sample MR design to estimate the correlation between autoimmune diseases and BMD-related drug targets. Data from the DrugBank and ChEMBL databases were used to identify the drug targets of anti-osteoporosis medications. The Wald ratio test or inverse-variance weighting method was used to assess the impact of genetic variation in drug target(s) on autoimmune disease therapy.
UNASSIGNED: Through our analysis, we discovered a negative correlation between genetic variability in a specific gene (ESR1) in raloxifene/colecalciferol and various autoimmune disorders such as ankylosing spondylitis, endometriosis, IgA nephropathy, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and type 1 diabetes.
UNASSIGNED: These results indicate a possible link between genetic differences in the drug targeting ESR1 and susceptibility to autoimmune disorders. Hence, our study offers significant support for the possible use of drugs targeting ESR1 for the management of autoimmune disorders. MR and drug repurposing are utilized to investigate the relationship between autoimmune diseases and bone mineral density, with a focus on ESR1.
UNASSIGNED: Using summary statistics from genome-wide association studies, we used a two-sample MR design to estimate the correlation between autoimmune diseases and BMD-related drug targets. Data from the DrugBank and ChEMBL databases were used to identify the drug targets of anti-osteoporosis medications. The Wald ratio test or inverse-variance weighting method was used to assess the impact of genetic variation in drug target(s) on autoimmune disease therapy.
UNASSIGNED: Through our analysis, we discovered a negative correlation between genetic variability in a specific gene (ESR1) in raloxifene/colecalciferol and various autoimmune disorders such as ankylosing spondylitis, endometriosis, IgA nephropathy, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and type 1 diabetes.
UNASSIGNED: These results indicate a possible link between genetic differences in the drug targeting ESR1 and susceptibility to autoimmune disorders. Hence, our study offers significant support for the possible use of drugs targeting ESR1 for the management of autoimmune disorders. MR and drug repurposing are utilized to investigate the relationship between autoimmune diseases and bone mineral density, with a focus on ESR1.
摘要：
■尽管治疗自身免疫性疾病的药物越来越多，许多患者仍在努力实现他们的治疗目标。我们的目的是确定最初用于治疗骨密度的药物是否可以通过孟德尔随机化（MR）应用于自身免疫性疾病的治疗。
■使用全基因组关联研究的汇总统计数据，我们使用双样本MR设计来评估自身免疫性疾病与BMD相关药物靶点之间的相关性.来自DrugBank和ChEMBL数据库的数据用于确定抗骨质疏松药物的药物靶标。使用Wald比率检验或逆方差加权方法来评估药物靶标中的遗传变异对自身免疫疾病治疗的影响。
■通过我们的分析，我们发现雷洛昔芬/coecalcierol中特定基因（ESR1）的遗传变异与各种自身免疫性疾病（如强直性脊柱炎）之间存在负相关，子宫内膜异位症,IgA肾病,类风湿性关节炎,结节病,系统性红斑狼疮,1型糖尿病。
■这些结果表明，针对ESR1的药物的遗传差异与自身免疫性疾病的易感性之间可能存在联系。因此，我们的研究为可能使用针对ESR1的药物治疗自身免疫性疾病提供了重要支持.利用MR和药物再利用来研究自身免疫性疾病与骨密度之间的关系。重点是ESR1。
■使用全基因组关联研究的汇总统计数据，我们使用双样本MR设计来评估自身免疫性疾病与BMD相关药物靶点之间的相关性.来自DrugBank和ChEMBL数据库的数据用于确定抗骨质疏松药物的药物靶标。使用Wald比率检验或逆方差加权方法来评估药物靶标中的遗传变异对自身免疫疾病治疗的影响。
■通过我们的分析，我们发现雷洛昔芬/coecalcierol中特定基因（ESR1）的遗传变异与各种自身免疫性疾病（如强直性脊柱炎）之间存在负相关，子宫内膜异位症,IgA肾病,类风湿性关节炎,结节病,系统性红斑狼疮,1型糖尿病。
■这些结果表明，针对ESR1的药物的遗传差异与自身免疫性疾病的易感性之间可能存在联系。因此，我们的研究为可能使用针对ESR1的药物治疗自身免疫性疾病提供了重要支持.利用MR和药物再利用来研究自身免疫性疾病与骨密度之间的关系。重点是ESR1。
